2.01
+0.14(+7.49%)
Currency In USD
| Previous Close | 1.87 |
| Open | 1.96 |
| Day High | 2.15 |
| Day Low | 1.91 |
| 52-Week High | 12.51 |
| 52-Week Low | 1.64 |
| Volume | 19.49M |
| Average Volume | 13.58M |
| Market Cap | 671.21M |
| PE | -1.65 |
| EPS | -1.22 |
| Moving Average 50 Days | 2.08 |
| Moving Average 200 Days | 5.64 |
| Change | 0.14 |
If you invested $1000 in Iovance Biotherapeutics, Inc. (IOVA) 10 years ago, it would be worth $220.15 as of July 14, 2025 at a share price of $2.01. Whereas If you bought $1000 worth of Iovance Biotherapeutics, Inc. (IOVA) shares 5 years ago, it would be worth $68.51 as of July 14, 2025 at a share price of $2.01.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi® in Patients with Advanced Melanoma
GlobeNewswire Inc.
10 hours ago
61% Response Rate Observed in Third-Line or Earlier Patients SAN CARLOS, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering no
Iovance Biotherapeutics Appoints Marc R. Theoret, M.D. as Senior Vice President, Regulatory Strategy
GlobeNewswire Inc.
Jul 10, 2025 8:01 PM GMT
SAN CARLOS, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies
Iovance Biotherapeutics to Present at Upcoming Conference
GlobeNewswire Inc.
Jun 10, 2025 12:45 PM GMT
SAN CARLOS, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patient